Development of a lateral flow aptamer assay strip for facile identification of theranostic exosomes isolated from human lung carcinoma cells

Yu, Qiang; Zhao, Qian; Wang, Sai; Zhao, Shuai; Zhang, Shan; Yin, Yingai; Dong, Yiyang

doi:10.1016/j.ab.2020.113591

Cited by 43 publications

(31 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exosomes were first reported by Trams et al (1981), Xin et al (2014); Witwer and Théry (2019). They were discovered in in vitro cell culture of sheep red blood cell supernatants with structural size ranging from 40 to 200 nm (Yu et al, 2020). Exosomes are the most important subtype of EVs, whereas the literature also contains other EV subtypes, including microvesicles, apoptotic bodies, blebs, exomeres, migrasomes, oncosomes, and argosomes classified by size, biogenesis, origin, content, and function (Ma et al, 2015;Xie et al, 2020) (Figure 1).…”

Section: Overview Of Exosome Biogenesismentioning

confidence: 99%

Native and Bioengineered Exosomes for Ischemic Stroke Therapy

Khan

Pan

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Exosomes are natural cells-derived vesicles, which are at the forefront toward clinical success for various diseases, including cerebral ischemia. Exosomes mediate cell-to-cell communication in different brain cells during both physiological and pathological conditions. Exosomes are an extensively studied type of extracellular vesicle, which are considered to be the best alternative for stem cell–based therapy. They can be secreted by various cell types and have unique biological properties. Even though native exosomes have potential for ischemic stroke therapy, some undesirable features prevent their success in clinical applications, including a short half-life, poor targeting property, low concentration at the target site, rapid clearance from the lesion region, and inefficient payload. In this review, we highlight exosome trafficking and cellular uptake and survey the latest discoveries in the context of exosome research as the best fit for brain targeting owing to its natural brain-homing abilities. Furthermore, we overview the methods by which researchers have bioengineered exosomes (BioEng-Exo) for stroke therapy. Finally, we summarize studies in which exosomes were bioengineered by a third party for stroke recovery. This review provides up-to-date knowledge about the versatile nature of exosomes with a special focus on BioEng-Exo for ischemic stroke. Standard exosome bioengineering techniques are mandatory for the future and will lead exosomes toward clinical success for stroke therapy.

show abstract

Section: Overview Of Exosome Biogenesismentioning

confidence: 99%

Native and Bioengineered Exosomes for Ischemic Stroke Therapy

Khan

Pan

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…These molecules can be used as a possible alternative to mAbs in biomedical research, since they have affinities and specificities comparable to those of Abs for various molecules [105,[108][109][110][111][112][113][114][115][116][117][118][119][120][121][122][123][124].…”

Section: Perspectivesmentioning

confidence: 99%

Monoclonal Antibodies Application in Lateral Flow Immunochromatographic Assays for Drugs of Abuse Detection

et al. 2021

View full text Add to dashboard Cite

Lateral flow assays (lateral flow immunoassays and nucleic acid lateral flow assays) have experienced a great boom in a wide variety of early diagnostic and screening applications. As opposed to conventional examinations (High Performance Liquid Chromatography, Polymerase Chain Reaction, Gas chromatography-Mass Spectrometry, etc.), they obtain the results of a sample’s analysis within a short period. In resource-limited areas, these tests must be simple, reliable, and inexpensive. In this review, we outline the production process of antibodies against drugs of abuse (such as heroin, amphetamine, benzodiazepines, cannabis, etc.), used in lateral flow immunoassays as revelation or detection molecules, with a focus on the components, the principles, the formats, and the mechanisms of reaction of these assays. Further, we report the monoclonal antibody advantages over the polyclonal ones used against drugs of abuse. The perspective on aptamer use for lateral flow assay development was also discussed as a possible alternative to antibodies in view of improving the limit of detection, sensitivity, and specificity of lateral flow assays.

show abstract

“…These exosomes can be medically identified through the specific characterization of membrane proteins. Inspired by LFIA and the advantages of aptamer, Yu et al [27] developed a lateral flow aptamer assay (LFAA) strip for the facile identification of A549 exosomes isolated from human lung carcinoma cells based on the specific binding of aptamer with CD63 protein (Fig. 5.4).…”

Section: Detection Of Other Substancesmentioning

confidence: 99%

Aptamer-Based Medical Devices

Liu

Wang

Zhang

2021

Aptamers for Medical Applications

View full text Add to dashboard Cite

Medical devices have undergone an evolution over thousands of years with the intention to improve the health of people. Aptamers are single-stranded nucleotides that can specifically bind to their targets. They are promising alternatives of antibodies in the field of medical devices owing to the property of specific binding to their targets, as well as the advantages such as easy synthesis and modification, chemical stability, low immunogenicity, and competitive cost, etc. Nevertheless, to our knowledge, there are no aptamer-based medical devices officially approved in the market. Therefore, in this chapter, we first introduced the definition, history, and market of medical devices. Then, some potentially prototypical aptamer-based medical devices related clinical trials, patents, and papers were introduced from two aspects according to their application in "diagnosis" and "therapies," respectively. Finally, we proposed our perspectives and insights for the development of aptamerbased medical devices.

show abstract

Development of a lateral flow aptamer assay strip for facile identification of theranostic exosomes isolated from human lung carcinoma cells

Cited by 43 publications

References 19 publications

Native and Bioengineered Exosomes for Ischemic Stroke Therapy

Native and Bioengineered Exosomes for Ischemic Stroke Therapy

Monoclonal Antibodies Application in Lateral Flow Immunochromatographic Assays for Drugs of Abuse Detection

Aptamer-Based Medical Devices

Contact Info

Product

Resources

About